Simavita (SVA)

Business description

Simavita listed on TSX-V in Dec 2013 and ASX in Feb 2014. Its SIM platform technology is an integrated assessment device that helps manage urinary incontinence. The devices are used in residential and nursing home settings to optimise incontinence care.

A golden opportunity

Initiation | Pharmaceutical & healthcare | 01/05/2014

Simavita is pioneering the use of its proprietary SIM (Smart Incontinence Management) platform to improve the outcomes and costs associated with urinary incontinence in residential care settings. As a launch into the important US market is planned for May, the next 12 to 18 months should mark the defining events on Simavita’s journey towards sustainable profitability. Our DCF model suggests a valuation of A$104m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.A$2.6m
Last closeA$0.022
High / Low (52 weeks)A$0.1 / A$0.0
Stock market listingAU
Forecast net cash (A$m)10.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(4.3)(26.7)(56.2)
Relative *(5.4)(27.6)(58.3)

* % Relative to local index

Company news